论文部分内容阅读
甲氧氯普胺作为胃动力剂在美国于80年代起用于治疗婴幼儿胃食管反流症(GER),未见该药新生儿体内药物动力学研究报导,本文以10名早产新生儿;其中男9,女1,孕龄31-40周,体重1.14～3.20kg的GER患儿为对象,研究了其体内的药代动力学特点.用反相高效液相法(HPLC)测定了9名早产儿的血药浓度,单剂口服0.1mg/kg或0.15mg/kg甲氧氯普溶液后0,0.5,l,2,3,6,12,18,24h采取血样.血药浓度—时间关系表明,符合一级动力学一室开放模型.本组新生儿药物动力学参数为 Ke 0.129±0.083～L/h;Ka1.86±2.42～L/h;AUC219.87±183.20ng/ml·h,Cmax17.72±6.20ng/ml;t_(max)2.41±1.07h,CL/F 0.795±0.682～L/h·kg,Vdss/F 6.94±2.39～L/kg,算得消除半衰期t e1/2 5.4h,吸收相半衰期t_(A1/2)为0.37h.C_(max)与t_(max)等与胎龄无关.与以往研究的婴儿药动学参数结果无统计学意义的
Metoclopramide as a gastric motility agent in the United States from the 80’s for the treatment of infantile gastroesophageal reflux disease (GER), no evidence of neonatal pharmacokinetics of the drug reported in this paper, 10 preterm neonates; Male 9, female 1, gestational age 31-40 weeks, body weight 1.14 ~ 3.20kg of GER children as object, the pharmacokinetic characteristics of its study in vivo by reverse-phase high-performance liquid chromatography (HPLC) measured 9 Blood concentration of preterm children, a single oral administration of 0.1mg / kg or 0.15mg / kg methoclop solution 0,0.5,1,2 2,36,12,18,24h blood samples taken blood concentration - time The results showed that the first-order kinetic model was fitted to the first-order kinetic model, and the pharmacokinetic parameters of newborns in this group were Ke 0.129 ± 0.083 ~ L / h, Ka 1.86 ± 2.42 ~ L / h, AUC219.87 ± 183.20ng / ml · h, Cmax17.72 ± 6.20ng / ml; t max (max) 2.41 ± 1.07h, CL / F 0.795 ± 0.682 ~ L / h · kg and Vdss / F 6.94 ± 2.39 ~ L / 2 5.4h, the half-life of the absorption phase was (t 1 / A1 2) 0.37h.C max and t max were not related to gestational age, which were not significantly different from those of previous studies